Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

11/03/2016 - 1 minute

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located.

mission_therapeutics_biotech_cancer_neil_woodford_dubsCity: Cambridge (UK)

Founded: 2011

Employees: 30

Total raised: €110M (as of 02/2016)

CEO: Anker Lundemose

mission_therapeutics_biotech

Mission: Founded in 2011, Mission Therapeutics, a private drug discovery company, aims to commercialize highly expert research towards the treatment of cancer and other diseases via the ubiquitin cell signalling pathway.

The company has built a well defined world-leading platform for the development of small molecule drugs that targets deubiquitylating enzymes (DUBs) involved in the DNA damage response. They work by inducing ‘synthetic lethality‘, a mechanism that selectively kills specific tumor cells in cancer.

Comment: The most impressive fact about the company was probably its last series C round of £60M (€75M) raised just last month.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member